Novo Nordisk Indonesia and Bio Farma have announced the signing of a Memorandum of Understanding (MoU) to collaborate in the production process of diabetes medication in Indonesia.

By combining the expertise of both companies, Novo Nordisk Indonesia and Bio Farma aim to support the Indonesian government in providing essential diabetes medications. This collaboration aligns with the government's agenda for healthcare resilience.

The increasing prevalence of diabetes in Indonesia underscores the importance of this collaboration. Currently, it is estimated that 19.5 million people live with diabetes, and this number is projected to rise to 28.6 million by 2045. This chronic condition is among the top three causes of death in Indonesia, highlighting the need for effective diabetes management.

Many people with diabetes in Indonesia face significant challenges in managing their condition due to limited knowledge and awareness about the disease and proper management. A 2020 report by the Social Security Administration (BPJS) revealed that only 2 million people are diagnosed and treated under the national healthcare system (Jaminan Kesehatan Nasional, JKN). This is concerning, especially since the 2023 Indonesian Health Survey (SKI) estimates that 80.6% of diagnosed and treated individuals have uncontrolled diabetes.

Novo Nordisk brings its expertise in diabetes care and insulin production to this collaboration, while Bio Farma contributes its established local manufacturing capabilities. By combining the strengths of both parties, this partnership aims to create a stronger and more sustainable foundation for diabetes management in Indonesia.